
Please try another search
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its develops oral Proprotein Convertase Subtilisin/Kexin Type 9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce long-term disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Name | Age | Since | Title |
---|---|---|---|
Rudiger Weseloh | - | 2019 | Independent Non-Executive Director |
Junichi Nabekura | - | - | Member of Scientific Advisory Board |
Gary Housley | - | - | Chairman of Scientific Advisory Board |
Christopher Todd Cox | 59 | 2019 | Non-Executive Director |
Marcus Frampton | - | 2019 | Independent Non-Executive Director |
John Alexander Moore | 59 | 2019 | Non-Executive Chairman |
Gisela Mautner | - | 2022 | Non-Executive Director |
Ian E. Dixon | - | 2020 | Non-Executive Director |
Jim Palmer | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review